A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that adding pegylated IFN (IFN)a-2b to denileukin
diftitox improves the potential of denileukin diftitox alone to deplete regulatory T cells
(Tregs) and will thereby boost tumor immunity in patients with advanced-stage epithelial
ovarian cancers, enhancing treatment efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio Tyler Curiel